Call Now Open
2026 Oxford-Harrington Rare Disease Scholar Award
January 15, 2026
The Oxford-Harrington Rare Disease Centre (OHC), a partnership between the University of Oxford, UK and Harrington Discovery Institute at University Hospitals, Cleveland, Ohio, is seeking highly innovative projects for its 2026 Rare Disease Scholar Award, which accelerates promising therapeutics discoveries from academic labs...
Continue ReadingJuly 05, 2023
New Orleans, LA – LSU Health New Orleans today announced that has exercised its option to receive an exclusive license to certain early-stage technology designed to slow the progression of DNA repeat expansion disorders.In DNA repeat expansion disorders, a segment of repeated DNA expands within a gene to cause disease. The... Continue Reading
May 09, 2023
Harrington Discovery Institute and the American Society for Clinical Investigation seek nominations to recognize an outstanding achievement by a physician-scientist Continue Reading
May 01, 2023
Atsena Therapeutics announced that the FDA has cleared the company’s IND application for a Phase I/II clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS), featuring Harrington Scholar Shannon Boye, PhD, University of Florida. Continue Reading
April 26, 2023
10 physician-scientists have been selected for drug development grant to advance discoveries into the clinic Continue Reading
April 10, 2023
Unique program for physician-scientists to advance promising discoveries into medicines Continue Reading
April 03, 2023
Focus on glymphatic clearance, neurovascular health, and other novel approaches Continue Reading
March 07, 2023
2023 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Retinal Gene Therapy for Genetic Diseases Continue Reading
March 01, 2023
Newfound clarity on the longstanding “medical mystery” may lead to new line of drugs for oxygen delivery disorders, including peripheral artery disease, sickle cell disease, heart failure, and others Continue Reading
February 14, 2023
Thylacine Biotherapeutics Inc. entered into a license agreement with Columbia University for worldwide exclusive rights to develop and commercialize a novel antiviral peptide platform. Continue Reading
January 27, 2023
Sol-Gel Technologies, Ltd. announced today the acquisition of topically-applied patidegib, a hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome from PellePharm, Inc. Continue Reading